Test Prop. SubQ.
- Thread starter koi
- Start date
THE-DET-OAK
IncreasedMyT @ ULV
subQ will cleave faster.
The prop is not a special prop that can be injected subQ fellas, you can inject any T subQ.
that is marketing at its best, they jut made it "thin" so it can go through slin pin. you can get anything through a slin pin, as long as you backload.
BigBlackguy
New member
Greazy-Pickle
Senior Member
draw the plunger out of the back of slin and use other needle to load it.. and the prop is probably made with EO which is very thin like DET said.. Ive never tried the subq with test but ive used 1/2in slin pins IM many many times and it worked just fine.. never injected more than 1 cc at a time though..
Excellent. I'm definitely doing test prop on my next cycle sub-q. I wonder if it stings? Has anyone on here injected Vitamin B Complex sub-q? That hurts like a mo-fo!
I hate pinning my quads and glutes. Even after 11 successful injections I still get nervous, feel sick before and during doing it and then worry for days after about an abscess forming... I know, I'm a pussy LOL....
Unfortunately I read a post on a board once about a guy who got an abscess in his glute and had to have it cut out, something I wish I'd never read, the pictures didn't help either!
Koi.
I hate pinning my quads and glutes. Even after 11 successful injections I still get nervous, feel sick before and during doing it and then worry for days after about an abscess forming... I know, I'm a pussy LOL....
Unfortunately I read a post on a board once about a guy who got an abscess in his glute and had to have it cut out, something I wish I'd never read, the pictures didn't help either!
Koi.
Teutonic, I respect your knowledge, but I don't believe your statement about test absorption via sub-q to be accurate.
For example:
According to convention if we inject oil-based AAS into the fat layer beneath the skin and above the muscle (subcutaneous) it will impair absorption and could delay dissipation of drugs for many weeks or months.
New research conducted at the Royal Victoria Hospital in Canada at the endocrine clinic tested the viability of subcutaneous shots.
The study involved 22 patients who were using the clinic for testosterone replacement therapy. The AAS was testosterone enanthate. The subjects were instructed to self-administer their testosterone subcutaneously once per week. The same 1ml that would have been injected once every 2 weeks was divided up into .5ml weekly injections. Blood tests which were conducted periodically throughout the 1 year investigation were suprisingly and unquestionably consistent. For exactly 100% of patients enrolled, testosterone levels remained in the physiological (normal) range for the entire duration of the study. This included both peak and trough levels (high & low during each week). Furthermore injections were extremely well tolerated. Each patient took over 50 injections and not one single adverse reactionn was noticed at the injection site.
The investigation concluded that not only was subcutaneous testosterone enanthate a viable option as far as drug release , but it was safe, cheap and far more comfortable for their patients compared to intramuscular injections.
Well it may be unrealistic to inject a full throttle cycle via subcutaneous. Recall the patients were injecting .5ml a week. And we all know there are many aas users who far exceed this volume/dosage on a weekly basis. It also does not mean that every oil-based aas, even in low to moderate dosages, will be viable for subcutaneous. It is possible that some aas based on their preservatives, carriers, concentrations, or natural properties of active substances may be more irritating to local tissues when given subcutaneously.
Still the possibility of a subcutaneous cycle cannot be excluded especially for those using reasonable doses in the 1 ml range.
Saudi Med J, 2006 Dec;27(12):1843-6 courtesty of W. Llewellyn
Koi.
For example:
According to convention if we inject oil-based AAS into the fat layer beneath the skin and above the muscle (subcutaneous) it will impair absorption and could delay dissipation of drugs for many weeks or months.
New research conducted at the Royal Victoria Hospital in Canada at the endocrine clinic tested the viability of subcutaneous shots.
The study involved 22 patients who were using the clinic for testosterone replacement therapy. The AAS was testosterone enanthate. The subjects were instructed to self-administer their testosterone subcutaneously once per week. The same 1ml that would have been injected once every 2 weeks was divided up into .5ml weekly injections. Blood tests which were conducted periodically throughout the 1 year investigation were suprisingly and unquestionably consistent. For exactly 100% of patients enrolled, testosterone levels remained in the physiological (normal) range for the entire duration of the study. This included both peak and trough levels (high & low during each week). Furthermore injections were extremely well tolerated. Each patient took over 50 injections and not one single adverse reactionn was noticed at the injection site.
The investigation concluded that not only was subcutaneous testosterone enanthate a viable option as far as drug release , but it was safe, cheap and far more comfortable for their patients compared to intramuscular injections.
Well it may be unrealistic to inject a full throttle cycle via subcutaneous. Recall the patients were injecting .5ml a week. And we all know there are many aas users who far exceed this volume/dosage on a weekly basis. It also does not mean that every oil-based aas, even in low to moderate dosages, will be viable for subcutaneous. It is possible that some aas based on their preservatives, carriers, concentrations, or natural properties of active substances may be more irritating to local tissues when given subcutaneously.
Still the possibility of a subcutaneous cycle cannot be excluded especially for those using reasonable doses in the 1 ml range.
Saudi Med J, 2006 Dec;27(12):1843-6 courtesty of W. Llewellyn
Koi.
More here:
1: Saudi Med J. 2006 Dec;27(12):1843-6.Links
Subcutaneous administration of testosterone. A pilot study report.
Al-Futaisi AM, Al-Zakwani IS, Almahrezi AM, Morris D.
Department of Medicine, College of Medicine & Health Sciences, Sultan Qaboos University, Muscat, Oman. alfutaisi@squ.edu.om
OBJECTIVE: To investigate the effect of low doses of subcutaneous testosterone in hypogonadal men since the intramuscular route, which is the most widely used form of testosterone replacement therapy, is inconvenient to many patients. METHODS: All men with primary and secondary hypogonadism attending the reproductive endocrine clinic at Royal Victoria Hospital, Monteral, Quebec, Canada, were invited to participate in the study. Subjects were enrolled from January 2002 till December 2002. Patients were asked to self-administer weekly low doses of testosterone enanthate using 0.5 ml insulin syringe. RESULTS: A total of 22 patients were enrolled in the study. The mean trough was 14.48 +/- 3.14 nmol/L and peak total testosterone was 21.65 +/- 7.32 nmol/L. For the free testosterone the average trough was 59.94 +/- 20.60 pmol/L and the peak was 85.17 +/- 32.88 pmol/L. All of the patients delivered testosterone with ease and no local reactions were reported. CONCLUSION: Therapy with weekly subcutaneous testosterone produced serum levels that were within the normal range in 100% of patients for both peak and trough levels. This is the first report, which demonstrated the efficacy of delivering weekly testosterone using this cheap, safe, and less painful subcutaneous route.
PMID: 17143361 [PubMed - indexed for MEDLINE]
1: Saudi Med J. 2006 Dec;27(12):1843-6.Links
Subcutaneous administration of testosterone. A pilot study report.
Al-Futaisi AM, Al-Zakwani IS, Almahrezi AM, Morris D.
Department of Medicine, College of Medicine & Health Sciences, Sultan Qaboos University, Muscat, Oman. alfutaisi@squ.edu.om
OBJECTIVE: To investigate the effect of low doses of subcutaneous testosterone in hypogonadal men since the intramuscular route, which is the most widely used form of testosterone replacement therapy, is inconvenient to many patients. METHODS: All men with primary and secondary hypogonadism attending the reproductive endocrine clinic at Royal Victoria Hospital, Monteral, Quebec, Canada, were invited to participate in the study. Subjects were enrolled from January 2002 till December 2002. Patients were asked to self-administer weekly low doses of testosterone enanthate using 0.5 ml insulin syringe. RESULTS: A total of 22 patients were enrolled in the study. The mean trough was 14.48 +/- 3.14 nmol/L and peak total testosterone was 21.65 +/- 7.32 nmol/L. For the free testosterone the average trough was 59.94 +/- 20.60 pmol/L and the peak was 85.17 +/- 32.88 pmol/L. All of the patients delivered testosterone with ease and no local reactions were reported. CONCLUSION: Therapy with weekly subcutaneous testosterone produced serum levels that were within the normal range in 100% of patients for both peak and trough levels. This is the first report, which demonstrated the efficacy of delivering weekly testosterone using this cheap, safe, and less painful subcutaneous route.
PMID: 17143361 [PubMed - indexed for MEDLINE]
